[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thalassemia-majors-beta-thalassemia-major\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thalassemia-majors-beta-thalassemia-major":111},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,37,61,88],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":16,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100632154",false,"NCT07509996","Risk Factors Affecting Growth in Thalassemic Children at AUCH","The Effect of Different Risk Factors on Growth Parameters of Thalassemic Patients in Assiut University Children Hospital","Inclusion Criteria:\n\n* Children aged 1 to 18 years diagnosed with β-thalassemia major based on hemoglobin electrophoresis or high-performance liquid chromatography (HPLC).\n* Receiving regular blood transfusions as part of standard management at AUCH.\n* Attending the hematology unit for at least one year prior to enrollment.\n\nExclusion Criteria:\n\n* • Children with other types of thalassemia.\n\n  * Presence of congenital diseases, chronic illnesses other than thalassemia (e.g., malignancy, tuberculosis, chronic hepatitis, congenital heart disease, chronic renal failure, epilepsy, diabetes mellitus), or primary endocrinopathies.\n  * Patients with other causes of short stature, such as hereditary bone dysplasia or systemic disorders.","ALL","12 Months","18 Years",{"count":19,"type":20},85,"ESTIMATED","OBSERVATIONAL","Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.",[24],"Thalassemia Majors (Beta-Thalassemia Major)","NOT_YET_RECRUITING","2026-03-28",{"date":28,"type":29},"2026-04-03","ACTUAL",{"date":31,"type":20},"2026-04-01",{"date":33,"type":20},"2027-05-01",{"name":35,"class":36},"Assiut University","OTHER",{"id":38,"slug":4,"hasResults":10,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":45,"maxAge":17,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":50,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":4},"100615142","NCT07288762","Gonadal Function in Thalassemic Patient","Gonadal Function in Boys With Transfusion Depandant Beta Thalassemia","Inclusion Criteria:\n\n* transfusion depandant beta thalassemia\n* age 10 to 18 year old age\n\nExclusion Criteria:\n\n* age below 10 year old age or above 18 year old age\n* associated with another disease",true,"MALE","10 Years",{"count":47,"type":20},80,"Patient with transfusion depandant beta thalassemia with accumulation of iron in their body affect pituitary gland and gonades lead to impaired their functions .",[24],[51],"INSL3 or inhibin B hormone in transfusion depandant beta thalassemia","2025-12-04",{"date":54,"type":29},"2025-12-17",{"date":56,"type":20},"2025-12-07",{"date":58,"type":20},"2026-08-01",{"name":60,"class":36},"Sohag University",{"id":62,"slug":4,"hasResults":10,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":10,"sex":15,"minAge":17,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100591456","NCT06980662","The Effect of Laughter Yoga in Beta Thalassaemia Major Patients: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Diagnosed with Beta Thalassaemia major,\n* Over 18 years of age,\n* No hearing and communication problems,\n* The one with the smartphone\n* Routine treatment with iron chelators, folic acid and magnesium\n* Do not have a physical problem that will prevent yoga exercises (bleeding haemorrhoids, all kinds of hernia, persistent cough, incontinence, severe back pain, hypertension, major psychiatric diseases, pregnancy, flu, epilepsy, surgery in the last 3 months, etc.)\n* Depression-Anxiety-Stress scale scores of 10 and above for depression (depressed), 8 and above for anxiety (anxious), 15 and above for stress (stressed)\n* Beta thalassaemia major patients who volunteered to participate in the study will be included in the study sample\n\nExclusion Criteria:\n\n* Who doesn't practice laughter yoga\n* Changing the treatment regime\n* Patients who wish to withdraw from the study","65 Years",{"count":68,"type":20},60,"INTERVENTIONAL",[71],"NA","The aim of this study was to evaluate the effects of laughter yoga on Fatigue, Depression-Anxiety-Stress, Sleep quality, Haematological values and Blood transfusion number in Beta Thalassemia Major patients.",[74,24],"Beta Thalassemia Major",[76,77],"Nursing, Fatigue, Depression-Anxiety-Stress and Sleep quality","fatigue","2025-05-12",{"date":80,"type":29},"2025-05-20",{"date":82,"type":20},"2025-06-01",{"date":84,"type":20},"2025-08-31",{"name":86,"class":36},"Ataturk University",1,{"id":89,"slug":4,"hasResults":10,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":10,"sex":15,"minAge":93,"maxAge":45,"enrollmentInfo":94,"targetDuration":4,"studyType":69,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100572534","NCT06734520","Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia","Inclusion Criteria:\n\n1. Diagnosis of severe β -thalassemia\n2. Age between 7-10 years old, male and female; Weight \\\u003C 40kg\n3. The patient has or does not have an HLA-compatible or semi-compatible donor, but unconditional transplantation or refusal of blood stem cell transplantation; Patients with thalassemia gene therapy without conditions or refusal;\n4. There are fully compatible or incompatible HLA donors, and the physical examination meets the donor conditions;\n5. The patient and family members agree to receive hypertransplant therapy and sign a written informed consent prior to the transplant trial.\n\nExclusion Criteria:\n\n1. Mental patients;\n2. Participants in other drug clinical trials within the past 1 month;\n3. There are no suitable HLA-incompatible donors.\n4. Other researchers decide that it is not suitable to participate in this researcher.","7 Years",{"count":95,"type":20},3,[71],"This is a single-arm, open label, phase 1 study in subjects with beta-thalassemia. This study will evaluate the safety and efficacy of preconditioning-free super-transplantation on beta-thalassemia pediatric patients.",[24,99],"Haplo-identical Donors","RECRUITING","2024-12-12",{"date":103,"type":29},"2024-12-16",{"date":105,"type":29},"2024-10-01",{"date":107,"type":20},"2029-07-01",{"name":109,"class":36},"Guangzhou Women and Children's Medical Center",2,""]